427 related articles for article (PubMed ID: 30104286)
21. Interaction of cyclin-dependent kinase 12/CrkRS with cyclin K1 is required for the phosphorylation of the C-terminal domain of RNA polymerase II.
Cheng SW; Kuzyk MA; Moradian A; Ichu TA; Chang VC; Tien JF; Vollett SE; Griffith M; Marra MA; Morin GB
Mol Cell Biol; 2012 Nov; 32(22):4691-704. PubMed ID: 22988298
[TBL] [Abstract][Full Text] [Related]
22. Pan-Cancer Analysis of
Sokol ES; Pavlick D; Frampton GM; Ross JS; Miller VA; Ali SM; Lotan TL; Pardoll DM; Chung JH; Antonarakis ES
Oncologist; 2019 Dec; 24(12):1526-1533. PubMed ID: 31292271
[TBL] [Abstract][Full Text] [Related]
23. BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitors.
Paculová H; Kramara J; Šimečková Š; Fedr R; Souček K; Hylse O; Paruch K; Svoboda M; Mistrík M; Kohoutek J
Tumour Biol; 2017 Oct; 39(10):1010428317727479. PubMed ID: 29025359
[TBL] [Abstract][Full Text] [Related]
24. CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion.
Tien JF; Mazloomian A; Cheng SG; Hughes CS; Chow CCT; Canapi LT; Oloumi A; Trigo-Gonzalez G; Bashashati A; Xu J; Chang VC; Shah SP; Aparicio S; Morin GB
Nucleic Acids Res; 2017 Jun; 45(11):6698-6716. PubMed ID: 28334900
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer.
Quereda V; Bayle S; Vena F; Frydman SM; Monastyrskyi A; Roush WR; Duckett DR
Cancer Cell; 2019 Nov; 36(5):545-558.e7. PubMed ID: 31668947
[TBL] [Abstract][Full Text] [Related]
26. Human CDK12 and CDK13, multi-tasking CTD kinases for the new millenium.
Greenleaf AL
Transcription; 2019 Apr; 10(2):91-110. PubMed ID: 30319007
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic Targeting of the General RNA Polymerase II Transcription Machinery.
Martin RD; Hébert TE; Tanny JC
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397434
[TBL] [Abstract][Full Text] [Related]
28. MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma.
Pitolli C; Marini A; Guerra M; Pieraccioli M; Marabitti V; Palluzzi F; Giacò L; Tamburrini G; Cecconi F; Nazio F; Sette C; Pagliarini V
J Exp Clin Cancer Res; 2023 Aug; 42(1):214. PubMed ID: 37599362
[TBL] [Abstract][Full Text] [Related]
29. The roles and therapeutic potential of cyclin-dependent kinases (CDKs) in sarcoma.
Liao Y; Feng Y; Shen J; Hornicek FJ; Duan Z
Cancer Metastasis Rev; 2016 Jun; 35(2):151-63. PubMed ID: 26669603
[TBL] [Abstract][Full Text] [Related]
30. CDK12 phosphorylates 4E-BP1 to enable mTORC1-dependent translation and mitotic genome stability.
Choi SH; Martinez TF; Kim S; Donaldson C; Shokhirev MN; Saghatelian A; Jones KA
Genes Dev; 2019 Apr; 33(7-8):418-435. PubMed ID: 30819820
[TBL] [Abstract][Full Text] [Related]
31. Ex vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcoma.
Bayles I; Krajewska M; Pontius WD; Saiakhova A; Morrow JJ; Bartels C; Lu J; Faber ZJ; Fedorov Y; Hong ES; Karnuta JM; Rubin B; Adams DJ; George RE; Scacheri PC
J Clin Invest; 2019 Oct; 129(10):4377-4392. PubMed ID: 31498151
[TBL] [Abstract][Full Text] [Related]
32. Identification and characterization of the CDK12/cyclin L1 complex involved in alternative splicing regulation.
Chen HH; Wang YC; Fann MJ
Mol Cell Biol; 2006 Apr; 26(7):2736-45. PubMed ID: 16537916
[TBL] [Abstract][Full Text] [Related]
33. Current progress and novel strategies that target CDK12 for drug discovery.
Lei P; Zhang J; Liao P; Ren C; Wang J; Wang Y
Eur J Med Chem; 2022 Oct; 240():114603. PubMed ID: 35868123
[TBL] [Abstract][Full Text] [Related]
34. Cdk12 Is A Gene-Selective RNA Polymerase II Kinase That Regulates a Subset of the Transcriptome, Including Nrf2 Target Genes.
Li X; Chatterjee N; Spirohn K; Boutros M; Bohmann D
Sci Rep; 2016 Feb; 6():21455. PubMed ID: 26911346
[TBL] [Abstract][Full Text] [Related]
35. EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma.
Iniguez AB; Stolte B; Wang EJ; Conway AS; Alexe G; Dharia NV; Kwiatkowski N; Zhang T; Abraham BJ; Mora J; Kalev P; Leggett A; Chowdhury D; Benes CH; Young RA; Gray NS; Stegmaier K
Cancer Cell; 2018 Feb; 33(2):202-216.e6. PubMed ID: 29358035
[TBL] [Abstract][Full Text] [Related]
36. Dissecting the Pol II transcription cycle and derailing cancer with CDK inhibitors.
Parua PK; Fisher RP
Nat Chem Biol; 2020 Jul; 16(7):716-724. PubMed ID: 32572259
[TBL] [Abstract][Full Text] [Related]
37. Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12/CycK complex.
Ekumi KM; Paculova H; Lenasi T; Pospichalova V; Bösken CA; Rybarikova J; Bryja V; Geyer M; Blazek D; Barboric M
Nucleic Acids Res; 2015 Mar; 43(5):2575-89. PubMed ID: 25712099
[TBL] [Abstract][Full Text] [Related]
38. Cyclin-dependent kinase inhibition: an opportunity to target protein-protein interactions.
Klein MA
Adv Protein Chem Struct Biol; 2020; 121():115-141. PubMed ID: 32312419
[TBL] [Abstract][Full Text] [Related]
39. The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer.
Ding L; Cao J; Lin W; Chen H; Xiong X; Ao H; Yu M; Lin J; Cui Q
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183020
[TBL] [Abstract][Full Text] [Related]
40. CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancer.
Lei H; Wang Z; Jiang D; Liu F; Liu M; Lei X; Yang Y; He B; Yan M; Huang H; Liu Q; Pang J
Cell Death Dis; 2021 Jul; 12(8):740. PubMed ID: 34315855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]